Research programme: cardiac disease therapies - Insilico Medicine/Tara Biosystems
Latest Information Update: 28 Feb 2023
At a glance
- Originator InSilico Medicine
- Developer InSilico Medicine; Tara Biosystems
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 03 Nov 2021 TARA Biosystems partners with Scipher Medicine to further drug discovery and development for Cardiac laminopathies
- 07 Jan 2019 Insilico Medicine and Tara Biosystems enters into a collaboration agreement to develop Cardiovascular disorder therapies